Cite
HARVARD Citation
Shapira-Frommer, R. et al. (n.d.). 2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. European journal of cancer. pp. S545-. [Online].